Newsroom



News

PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.



  • March 27, 2015
  • Researchers Uncover a Potential Non-invasive Test for Certain Types of Pulmonary Hypertension
  • (Pulmonary Hypertension News) Researchers from the German Center of Lung Research (DZL), Hannover Medical School in Germany recently released findings from a study in which they investigated the theory that the capillary pCO2 (pcCO2) may help in distinguishing between idiopathic pulmonary arterial hypertension (IPAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). An improvement in making an accurate diagnosis between these two disease types could lead to improved treatment and patient outcomes. The study entitled, “Capillary pCO2 helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction,” was published in the most recent edition of Respiratory Research.
  •   
  • Pulmonary arterial hypertension associated with chronic active Epstein-Barr virus infection.
  • (Pubmed) Chronic active Epstein-Barr virus (EBV) infection (CAEBV), characterized by persistent infectious mononucleosis-like symptoms, can lead to cardiovascular complications including coronary artery aneurysm or myocarditis. Here, we present the case of an 11-year-old boy with pulmonary arterial hypertension (PAH) and junctional ectopic tachycardia associated with CAEBV. The patient did not have any major symptoms attributed to CAEBV, such as fever, lymphadenopathy or splenomegaly when the PAH developed. Mild liver dysfunction was found at the first examination, and it persisted. Two years after the PAH symptoms appeared, CAEBV was evident, based on deteriorated liver function, hepatosplenomegaly, and coronary artery aneurysms. CAEBV should be considered as a cause of secondary PAH, particularly when liver dysfunction coexists.
  •   
  • March 26, 2015
  • Beneficial Effects of Renal Denervation on Pulmonary Vascular Remodeling in Experimental Pulmonary Artery Hypertension.
  • (pubmed) Activation of both the sympathetic nervous system and the renin-angiotensin-aldosterone system is closely associated with pulmonary arterial hypertension. We hypothesized that renal denervation decreases renin-angiotensin-aldosterone activity and inhibits the progression of pulmonary arterial hypertension.
    [..]
    Renal denervation attenuates pulmonary vascular remodeling and decreases pulmonary arterial pressure in experimental pulmonary arterial hypertension. The effect of renal denervation may contribute to decreased neurohormone levels.
  •   
  • Reported sildenafil side effects in pediatric pulmonary hypertension patients.
  • (PubMed) Click headline for more, please.
  •   
  • March 25, 2015
  • Bellerophon Therapeutics Selects Flextronics to Manufacture the Mark2, Next-Generation INOpulse(R) Device
  • (CNN) Bellerophon's INOpulse is a drug-device combination system that is targeted to reducing pulmonary hypertension in patients with this condition including those with PAH and PH-COPD. The INOpulse system is designed to deliver pulsed doses of pharmaceutical-grade nitric oxide, a molecule naturally produced in the endothelial lining of blood vessels that plays a significant role in vasodilation, or opening of the arteries, including arteries in the lung.

    Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics, noted, "We are pleased to work with Flextronics, an established, global leader, for the manufacturing of our next-generation device. This new device is significantly smaller, lighter and more user friendly than the previous version, which we believe will help patients to be more compliant with their therapy. Flextronics' experience with manufacturing medical devices, including portable drug delivery systems, was important to us, and we look forward to working with them to have devices ready for our upcoming Phase 3 trials for the treatment of pulmonary arterial hypertension (PAH) which we expect to commence in the second half of 2015."
  •   
  • Cystic Fibrosis Discovery Provides Insight into Other Pulmonary Conditions - See more at: http://www.hcplive.com/news/Cystic-Fibrosis-Discovery-Provides-Insight-into-Other-Pulmonary-Conditions#sthash.kijEQvsi.dpuf
  • (HCP Live) In patients with cystic fibrosis (CF), mucus’ molecular bonds become more complex due to inflammation, creating an “elastic sludge” effect, according to a team of researchers from University of California San Francisco (UCSF) who claimed their findings could also be beneficial for other respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma.
  •   
  • March 24, 2015
  • Risk for Anesthesia Complications Still High In Children With Pulmonary Hypertension
  • (Anesthesiolgy News) Children with pulmonary hypertension (PHT) are still at a high risk for adverse events during anesthesia even when using the latest disease-modifying treatments, according to a new study.
  •   
  • Sildenafil therapy in bronchopulmonary dysplasia-associated PH: a retrospective study of efficacy and safety
  • (Springer.com) Sildenafil therapy was associated with a significant improvement in the echocardiographic markers of PAH and a reduction in FiO2. The medication was well tolerated...
  •   
  • March 23, 2015
  • Prognostic potential for pericardial effusion in PAH patients
  • (News Medical) Monitoring pericardial effusion on serial transthoracic echocardiograms (TTEs) provides useful prognostic information in patients with pulmonary arterial hypertension (PAH), research suggests.
  •   
  • March 22, 2015
  • Combining CT measurements assists pulmonary hypertension prediction
  • (News Medical) Research suggests that combining pulmonary artery (PA) and ventricular measurements improves the chances of identifying pulmonary hypertension (PH) in patients undergoing computed tomography pulmonary angiography (CTPA).
  •   
  • Boy's 26 arterial narrowings fixed in one fell swoop
  • (Health Canal) Cardiothoracic surgeon Frank Hanley corrected more than two dozen pulmonary artery narrowings in a 6-year-old patient during one marathon surgery.
  •   
  • March 21, 2015
  • Issues remain in treatment diagnosis of PH in patients with inflammatory rheumatic diseases
  • (Healio) Unresolved issues were present in the treatment and diagnosis of early pulmonary hypertension in patients with inflammatory rheumatic diseases, who are at higher risk for pulmonary arterial hypertension, according to researchers at the Hacettepe University Faculty of Medicine in Ankara, Turkey.
  •   
  • Selten's PAH treatment tacrolimus gets FDA orphan drug status
  • (Regulatory Affairs) The company said that SPI-026 prevented the development of PAH in mice with a deletion of BMPR2 endothelial cells in a chronic hypoxia model, and reversed PAH and neointimal/occlusion in the lungs in rats with neointima formation following VEGF receptor blockade and chronic hypoxia.
  •   
  • March 20, 2015
  • Computed Tomography Pulmonary Angiography Measurements Shown as a Predictive Tool for Pulmonary Hypertension
  • (Lung Disease News) Researchers at the VU University Medical Center in Amsterdam, The Netherlands recently published findings in The International Journal of Cardiovascular Imaging that reveal specific measurements obtained by standard computed tomography pulmonary angiography (CTPA) can be used as an accurate predictive tool for pulmonary hypertension. The study is entitled “Predicting pulmonary hypertension with standard computed tomography pulmonary angiography.”
  •   
  • New Cellular Proliferation Protein Observed in Idiopathic Pulmonary Arterial Hypertension
  • (Pulmonary Hypertension News) Researchers at the Cleveland Clinic recently published findings in the journal Circulation revealing that a protein linked to the glucose metabolism pathway can promote cellular proliferation in lung tissues of individuals with idiopathic pulmonary arterial hypertension (IPAH). The study is entitled “O-GlcNAc Transferase Directs Cell Proliferation in Idiopathic Pulmonary Arterial Hypertension.”
  •   
  • March 19, 2015
  • COPD Patients with Pulmonary Hypertension are More Prone to Co-Morbidities
  • (Lung Disease News) Researchers at the Cairo University in Egypt recently reported that patients with chronic obstructive pulmonary disease (COPD) can also develop co-morbidities as pulmonary hypertension and cardiac alterations. The study was published in the Egyptian Journal of Chest Diseases and Tuberculosis and is entitled “Detection of right sided heart changes and pulmonary hypertension in COPD patients.”
  •   
  • Small Study Suggests Benefits of Denervation for PAH
  • (TCTMD) Before-and-after study evaluates pulmonary artery denervation for patients with various types of pulmonary hypertension
    Procedure appears to improve functional, hemodynamic outcomes.


  •   
  • March 18, 2015
  • Pulmokine Receives $1M Investment to Further PAH Drug Development
  • (Pulmonary Hypertension News) The therapy candidate is designed to inhibit the PDGF receptor kinase in order to decrease and possibly even reverse the proliferation of pulmonary cells that cause PAH. Pulmokine has already conducted preclinical studies revealing that patients dosed with PK10571 had their pulmonary artery systolic pressure reduced, a crucial indicator of PAH.
  •   
  • March 17, 2015
  • Selexipag (Uptravi) long-term outcome data in pulmonary arterial hypertension
  • (Yahoo Finance) Actelion Ltd (ATLN.VX) today announced that key long-term outcome data from the pivotal selexipag (Uptravi®) Phase III GRIPHON study were shared during an oral presentation at the American College of Cardiology (ACC) Congress in San Diego, US. The presentation highlighted that the investigational drug selexipag significantly reduced the risk of a morbidity/mortality event by 40% versus placebo...
  •   
  • March 16, 2015
  • Discolored fingers? It could be Raynaud’s phenomenon
  • (Courier Post) Although winter is waning, lingering cold weather may cause people to suffer from a painful hand and foot disorder due to a condition called Raynaud’s phenomenon.  Common symptoms of Raynaud’s include fingers that are hypersensitive to the cold and turn white
  •   
  • Improved Quality in Assessment of Heart Function with EchoInsight
  • (Business Wire) Epsilon Imaging, Inc., a visualization and analysis software provider transforming cardiac diagnostic workflow, today announced four studies were presented at the ACC’ 15 Scientific Sessions; these studies all demonstrated improved quality in assessment of heart function with EchoInsight visualization and analysis. 
  •   
  • March 15, 2015
  • Idiopathic Pulmonary Fibrosis Outcomes Improved With Need-Based Allocation And Double Lung Transplants
  • (Pulmonary Fibrosis News) A new study published in the March 3 issue of the Journal of the American Medical Association (JAMA) finds that a medical need-based donor lung allocation protocol has been associated with better graft survival than single-lung transplantation procedures in persons afflicted with idiopathic pulmonary fibrosis (IPF).
  •   
  • Individual CTEPH Case Study Demonstrates Features of Heart Failure
  • (Pulmonary Hypertension News) A lot can change in five years, especially when someone has chronic thromboembolic pulmonary hypertension (CTEPH). A group of doctors at the University of Würzburg and Katharinen-Hospital Unna in Germany followed a 68-year-old woman for five years, from the time of her visiting the clinic with shortness of breath and symptoms of pooling fluid in both legs to the time of her death due to cardiogenic shock. Along the way, she was diagnosed with CTEPH, making the clinical case study an added piece of knowledge to understanding CTEPH progression.
  •   
  • March 14, 2015
  • Researchers Review Importance of Non-Invasive Imaging in Diagnosis and Management of PAH
  • (Lung Disease News) A recently accepted manuscript on the Canadian Journal of Cardiology, an open access journal, provides an overview of the current clinical use of noninvasive imagining techniques, such as echocardiography, for pulmonary arterial hypertension (PAH). The study investigators, led by Dr. Irene Lang, MD, Professorship of Vascular Biology, Department of Internal Medicine, Division of Cardiology, Medical University of Vienna Austria, conducted a thoroughly researched review that highlights the present role non-invasive imaging has and its potential to eventually replace hemodynamics as the standard approach to screening, diagnosing and managing PAH.
  •   
  • Results of SERAPHIN Trial Show Macitentan PAH Treatment Decreases Hospitalization Risk
  • (Lung Disease News) A group of international pulmonary medical specialists have conducted a clinical trial to assess improvement in hospital based outcomes in patients with pulmonary arterial hypertension (PAH) when treated with macitentan, an endothelin receptor antagonist. The study team, led by Dr. Nazzareno Galiè, MD, head of the Pulmonary Hypertension Center at the Institute of Cardiology, hospital readmissionAssociate Professor of Cardiology, University of Bologna, published their findings in the latest edition of Heart Failure, a journal of the American College of Cardiologists.
  •   
  • March 13, 2015
  • The Therapeutic Effects of Human Mesenchymal Stem Cells Primed with Sphingosine-1 Phosphate on Pulmonary Artery Hypertension.
  • (Pubmed) Stem cell (SC) therapy has become a potential treatment modality for pulmonary artery hypertension (PAH), but the efficacy of human SC and priming effects have not yet been established. The mobilization and homing of hematopoietic stem cells (HSCs) are modulated by priming factors that include a bioactive lipid, sphingosine-1-phosphate (S1P), which stimulates CXCR4 receptor kinase signalling. Here, we show that priming human mesenchymal stem cells (MSCs) with S1P enhances their therapeutic efficacy in PAH...
  •   
  • March 12, 2015
  • Meta Anaylsis shows improved survival and hospitalisation in pulmonary arterial hypertension
  • (Deutsche Ärztezeitung) Germany: A meta analysis of 23 randomised controlled trials for pulmonary arterial hypertension (PAH) showed 43% improvement in mortality and 61% less hospitalisations. (clicking the headline leads you to the German language article, but you can use an online translator to read more). 
  •   
  • Metabolic dysfunction in pulmonary arterial hypertension.
  • (Springer.com) Recent publications highlighting alterations in aerobic glycolysis, fatty acid oxidation, and the tricarboxylic acid cycle in the pulmonary circulation and right ventricle have expanded our understanding of the complex pathobiology of this disease. By targeting these derangements in metabolism, numerous researchers are investigating noninvasive techniques to monitor disease activity and therapeutics that address the underlying metabolic condition...
  •   
  • Study Reveals Stark Differences Between Medicare Advantage, Commercially Insured PAH Patients’ Healthcare Costs
  • (Pulmonary Hypertension News) According to a recent study published online in the American Journal of Managed Care, PH-related hospitalizations lead to high healthcare costs, with patients with PAH requiring long hospital stays. The study results also revealed that many patients with PAH are readmitted within 1 year of receiving their diagnosis. Based on the findings, researchers indicate the need for improved treatment methods to diminish the progression of PAH in order to reduce costs and burdens related with inpatient stays.
  •   
  • March 11, 2015
  • FDA Clears Corbus’ IND to Start Phase 2 Scleroderma Treatment Study
  • (Pulmonary Hypertension News) Clinical stage pharmaceutical company Corbus Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application allowing the company to begin a phase 2 clinical study to evaluate its treatment for diffuse cutaneous systemic sclerosis called Resunab.
  •   
  • Capillary pCO2 helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction
  • (7Th Space) RationaleThe demographics of patients with idiopathic pulmonary arterial hypertension (IPAH) are changing and this diagnosis is increasingly being made in older patients. However, diagnostic misclassifications are common as it may be difficult to differentiate between IPAH and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
  •   
  • March 10, 2015
  • Leptin signalling system as a target for pulmonary arterial hypertension therapy.
  • (European Respitatory Journal) click headline for more
  •   
  • Capillary pCO2 helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction
  • (7thspace.com) PcCO2 levels were significantly lower in IPAH compared to PH-HFpEF and may provide useful information in differentiating between both conditions.
  •   
  • March 9, 2015
  • Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension.
  • (Pubmed) By means of a genetic approach, new data provide definite evidence that the activated βPDGFR is a key contributor to pulmonary vascular remodeling and PAH. Selective disruption of PDGF-dependent phophatidyl-inositol-3-kinase and PLCγ activity is sufficient to abolish these pathogenic responses in vivo, identifying these signaling events as valuable targets for antiremodeling strategies in PAH.
  •   
  • March 8, 2015
  • Pulmokine Receives $1 Million Investment from Broadview Ventures to Advance PAH Candidate into First Clinical Trial
  • (GlobeNewswire) Pulmokine announced today that it has entered into an investment agreement with Broadview Ventures for $1 Million. Proceeds will be used to advance Pulmokine's lead candidate, PK10571, into Phase 1 clinical trials in patients with pulmonary arterial hypertension (PAH).
  •   
  • Scimitar syndrome with absent right pulmonary artery and severe pulmonary hypertension treated with coil occlusion of aortopulmonary collaterals in a term neonate
  • (BMJ) Scimitar syndrome (SS) is a rare congenital malformation with an estimated incidence of approximately 2 in 100?000 births. A wide clinical spectrum is observed in children with this syndrome. The common clinical presentation in infancy is respiratory distress and tachypnoea due to associated pulmonary hypoplasia, pulmonary overcirculation and/or pulmonary hypertension. Babies with SS presenting with cardiac failure are prone to develop exaggerated pulmonary vascular disease. Hence early intervention, using either coil embolisation or surgical intervention, is indicated.
  •   
  • March 7, 2015
  • Langerhans Cell Histiocytosis-Related PH Benefits from Advanced Therapies, According to Individual Case Study
  • (Pulmonary Hypertension News) In a new case-report study entitled “Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy,” authors describe vasodilators’ positive effects in treating Pulmonary Langerhans cell histiocytosis patients with known pulmonary hypertension. The study was published in the journal Respiratory Medicine Case Reports.
  •   
  • Enhancing and Inhibiting Autophagy in Lung Disease is Double-Edged
  • (Lung Disease News) Researchers from the Weill Cornell Medical College and New York-Presbyterian Hospital in New York recently discussed the role of autophagy in lung diseases in a study titled “Autophagy in lung disease pathogenesis and therapeutics,” recently published in the journal Redox Biology.
  •   
  • March 6, 2015
  • UCSF Liver Transplant Conference 2014: Porto-Pulmonary Hypertension
  • (uctv) Video
    Van Selby, MD discusses elevated pulmonary artery pressures due to increased resistance to blood flow in the setting of portal hypertension. The effects on and from liver transplantation are detailed.
  •   
  • Outcomes of lung transplantations since implementation of need-based allocation system
  • (Medical Xpress) Since implementation of a medical need-based allocation system of donor lungs in 2005, double-lung transplantation has been associated with better graft survival than single-lung transplantation in patients with idiopathic pulmonary fibrosis (IPF); at 5 years, there has been no survival difference between single- and double-lung transplant recipients in patients with chronic obstructive pulmonary disease (COPD), according to a study in the March 3 issue of JAMA.
  •   
  •  Canadians with rare, complex and fatal lung disease fearful of one-size-fits-all approach to treatment
  • (Canada News Wire) Canadians affected by pulmonary arterial hypertension (PAH) fear the threat of heart failure, or death, could soon be even more difficult to prevent given a recent recommendation to restrict patients' access to treatment.  PAH is a rapidly-progressing and difficult-to-treat rare lung disease with no regard for race or age and is fatal within two to three years if left untreated.  
  •   
  • Pulmonary hypertension frequent comorbidity in patients with aortic stenosis undergoing TAVR
  • (Helio) The study was conducted to evaluate the prevalence of pulmonary hypertension in this population and the long-term effects on pulmonary artery hemodynamics after TAVR. Researchers studied 415 consecutive patients with severe aortic stenosis (mean age, 84 years; 47% men; mean STS risk score, 10; mean logistic EuroSCORE, 30). All patients underwent TAVR with the Sapien or Sapien XT heart valves (Edwards Lifesciences) or the CoreValve (Medtronic) from 2007 to 2013 at MedStar Washington Hospital Center in Washington, D.C.
  •   
  • March 5, 2015
  • Pulmonary hypertension frequent comorbidity in patients with aortic stenosis undergoing TAVR
  • (Healio) The presence of pulmonary hypertension may independently predict poor short- and long-term outcomes after transcatheter aortic valve replacement in patients with severe aortic stenosis...
  •   
  • Diagnosis, Management of PAH Benefit From Non-invasive Imaging Methods, According to Study
  • (Pulmonary Hypertension News) A recent review on imaging of pulmonary vascular disease and the right ventricle by non-invasive techniques in the context of pulmonary arterial hypertension (PAH) was published in the Canadian Journal of Cardiology. The review entitled “Advanced imaging tools rather than hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension” was published by Dr. Mario Gerges, first author, and Dr. Christian Gerges and Dr. Irene M Lang, senior authors from the Department of Internal Medicine II, Division of Cardiology at the Medical University of Vienna, Austria.
  •   
  • Actelion's New Drug Application for selexipag (Uptravi) is accepted by the US FDA with a standard review time
  • (Nasdag) Actelion Pharmaceuticals Ltd / Actelion's New Drug Application for selexipag (Uptravi) is accepted by the US FDA with a standard review time . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
  •   
  • March 4, 2015
  • Selexipag (Uptravi) data in pulmonary arterial hypertension to be presented at American College of Cardiology (ACC) 2015
  • (Nasdaq) ALLSCHWIL, SWITZERLAND - 02 March 2015 - Actelion Ltd (SIX:ATLN) today announced that key data from the pivotal Phase III selexipag (Uptravi®) study will be shared during an oral presentation at the American College of Cardiology (ACC) Congress in San Diego, US. The abstract is now available on-line at the following link:

    http://www.abstractsonline.com/pp8/#!/3658/presentation/29719


    Read more: http://www.nasdaq.com/press-release/selexipag-uptravi-data-in-pulmonary-arterial-hypertension-to-be-presented-at-american-college-of-20150302-00667#ixzz3TOLVmem6
  •   
  • March 3, 2015
  • Beta Blocker Nebivolol Shows Promise In Pulmonary Arterial Hypertension
  • (Pulmonary Hypertension News) A French research team was able to demonstrate nebivolol’s beneficial effects in treating pulmonary arterial hypertension (PAH), suggesting that new clinical studies should be conducted to further test the drug. The study entitled: “Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function in Pulmonary Hypertension” was published on February 24, 2015 in the Journal of American College of Cardiology. Nebivolol is a third generation β1 receptor blocker with nitric oxide-potentiating vasodilatory effect.
  •   
  • 25 years of lung transplantation: "Second wind" from Vienna
  • (HalthCanal) (Vienna ) In November 1989, the first lung transplantation was performed at the medical faculty of the University of Vienna. 25 years later, the Medical University of Vienna or the AKH Wien is one of the four world-leading centres for lung transplantation along with Hannover, Toronto and Cleveland. 120 patients annually receive their "second wind" from Vienna.
  •   
  • March 2, 2015
  • Why Heart Rate Matters
  • (Amgen) According to RETROSPECTIVE ANALYSES, Heart rates of ≥ 70 bpm were associated with:
    ≥19% INCREASE in the risk of all-cause mortality in patients with left ventricular dysfunction (LVEF ≤ 40%)
    ≥25% INCREASE in the risk of the composite outcome of CV death or hospital stay for worsening HF in patients with left ventricular dysfunction (LVEF ≤ 40%)
  •   
  • UAB offers pulmonary medicine research symposium
  • (UAB News) The University of Alabama at Birmingham Division of Pulmonary, Allergy and Critical Care Medicine presents Pulmonary & Critical Care Update, 2015 on Friday and Saturday, April 10 and 11.

    Topics covered include risk factors, pathogenesis and management of COPD, asthma, ARDS and pulmonary hypertension.
  •   
  • March 1, 2015
  • Role for Telomerase in Pulmonary Hypertension
  • (Circulation) Cells exhibiting dysregulated growth may express telomerase reverse transcriptase (TERT), the dual function of which consists of maintaining telomere length, in association with the RNA template molecule TERC, and controlling cell growth. Here, we investigated lung TERT in human and experimental pulmonary hypertension (PH) and its role in controlling pulmonary artery smooth muscle cell (PA-SMC) proliferation.
  •   
  • SteadyMed Raises $12.2M to Advance PAH Therapy
  • (Pulmonary Hypertension News) Specialty pharmaceutical company SteadyMed Ltd. recently raised $12.2 million in equity financing, co-led by subsidiaries of Federated Investors Inc. and Deerfield Management Company L.P., as well as existing shareholders from the company. The funding will be invested in SteadyMed’s therapeutic product candidates for the treatment of orphan diseases, including pulmonary arterial hypertension (PAH).
  •   
  • February 28, 2015
  • CDC Says Influenza Vaccine Only 18% Effective This Year
  • (Medscape) The influenza vaccine this season has had little to no efficacy, in particular against the predominant A strains that have been circulating, said researchers from the Centers for Disease Control and Prevention (CDC) today.
  •   
  • Adempas Approved in Japan for the Treatment of Pulmonary Arterial Hypertension
  • (Financial) Following the approval of Adempas in January 2014 for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgery, Adempas is now the first drug approved in Japan to treat two forms of pulmonary hypertension (PH). The development and commercialization of riociguat is part of the worldwide strategic collaboration with Merck (through a subsidiary) in the field of soluble guanylate cyclase (sGC) modulation. Merck is known as MSD outside of the U.S. and Canada.
  •   

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives